An alternative treatment for metastatic CRC, HER2-positive EC, and advanced GC patients who exhibit Programmed Cell Death Ligand 1 (PD-L1) or microsatellite instability-high (MSI-H) biomarkers and are resistant to chemotherapy is pembrolizumab, an anti-PD-1 antibody, which functions by targeting the PD-1 receptor on tumor cells and preventing their evasion from the immune system. The gene discussed is CD274; the disease is neoplasm.